SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending due to a significant price surge, sparking debates about its potential as 'the new Bitcoin' and the impact of its privacy features. Community members are actively discussing entry and exit strategies amidst the volatility, while also comparing it to other cryptocurrencies.

Swell

Swell is gaining attention, with community members highlighting its low market cap and potential for staking rewards, encouraging others to spread the word. Some users believe it's poised for growth and discussing possible price targets, while others express concerns about potential scams and slow price action. The conversation also mentions Swell's connection to the Ethereum ecosystem and liquid staking.

CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Cel-Sci Corp.

CVM is trending as investors eagerly await news regarding the potential Breakthrough Medicine Designation from the Saudi Food and Drug Authority for its cancer treatment, Multikine. Community discussions revolve around the timeline for the decision, the implications of a potential partnership with Dallah Pharma, and speculation about Ergomed's recent share sales. Amidst the anticipation, there's a broader debate on the company's future prospects and financial stability.

DTE Energy Co. operates as a diversified energy company, which engages in the development and management of energy-related businesses and services. It operates through the following segments: Electric, Gas, DTE Vantage, Energy Trading, and Corporate and Other. The Electric segment consists of generation, purchase, distribution, and sale of electricity to residential, commercial, and industrial customers in southeastern Michigan. The Gas segment is involved in the purchase, storage, transportation, distribution, and sale of natural gas to residential, commercial, and industrial customers throughout Michigan, and the sale of storage and transportation capacity. The DTE Vantage segment focuses on projects that deliver energy and utility-type products and services to industrial, commercial, and institutional customers, produce reduced emissions fuel, and sell electricity and pipeline-quality gas from renewable energy projects. The Energy Trading segment covers energy marketing and trading operations. The Corporate and Other segment includes various holding company activities, holds certain non-utility debt, and holds certain investments, as well as funds supporting regional development and economic growth. The company was founded in January 1995 and is headquartered in Detroit, MI.

DTE Energy Co.

DTE Energy is trending due to a mix of factors, including analyst rating adjustments and discussions around the company's investments in clean energy and infrastructure. The community is focused on the balance between growth initiatives, debt, and potential risks, while also noting the hyperscale data center agreement and potential for increased energy demand.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is trending as the community discusses its potential for a violent move upwards and compares it to other cryptocurrencies like Zcash. Conversations also highlight accumulation patterns and speculation about an impending alt season, alongside discussions of potential ETF filings. Some traders are pointing to the BCH/BTC chart, suggesting an undervaluation compared to Bitcoin.

Dave, Inc. is a digital banking service. Its products include a budgeting tool to help members manage their upcoming bills to avoid overspending, cash advances through its flagship ExtraCash product to help members avoid punitive overdraft fees, a Side Hustle product, where Dave helps connect members with supplemental work opportunities, and Dave Banking, a modern checking account experience with valuable tools for building long-term financial health. The company was founded by Jason Wilk, Paras Chitrakar, and John Wolanin in October 2015 and is headquartered in Los Angeles, CA.

Dave Inc - Ordinary Shares - Class A

DAVE is trending due to a Department of Justice lawsuit alleging deceptive practices, with potential consumer redress exceeding $200 million, sparking concerns about the company's future. Despite this legal challenge, some community members remain optimistic, pointing to upcoming BNPL initiatives and strong Q3 2025 adjusted EBITDA margins. Recent analyst target price increases add to the mixed sentiment surrounding the stock.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer (ICP) is trending as the crypto community discusses its recent bullish momentum and potential as a decentralized cloud platform. Community members are pointing to its strong chart and AI capabilities while debating whether it can sustain its climb. Some are drawing comparisons to other altcoins that have experienced significant pumps.

Valero Energy Corp. engages in the manufacture and marketing of transportation fuels and other petrochemical products. It operates through the following business segments: Refining, Ethanol and Renewable Diesel. The Refining segment consists of refining operations, associated marketing activities, and logistics assets that support its refining operations. The Ethanol segment includes its ethanol operations, associated marketing activities, and logistics assets that support its ethanol operations. The Renewable Diesel covers the operations of Diamond Green Diesel Holdings LLC. The company was founded in 1980 and is headquartered in San Antonio, TX.

Valero Energy Corp.

Valero Energy (VLO) is trending amid rising crude oil prices and geopolitical tensions, particularly those impacting Russian oil supply.  The stock's recent breakout and analyst upgrades are fueling community discussion, with some anticipating a move towards new highs, while others express caution about valuation and profit-taking.

Hecla Mining Co. engages in the provision of precious and base metals. It operates through the following segments: Greens Creek, Lucky Friday, Keno Hill, Casa Berardi, and Other. The company was founded by Amasa B. Campbell, Patsy Clark, and John Finch on October 14, 1891 and is headquartered in Coeur d'Alene, ID.

Hecla Mining Co.

Hecla Mining is trending as traders discuss its potential as a silver sector leader, with some suggesting it's forecasting the moves of other miners. Bullish sentiment is fueled by potential breakouts from long-term wedges and options activity, while others are wary of intraday sell-offs and bearish price action. Community members are watching key silver levels, speculating on news catalysts, and eyeing potential upside targets amid discussions of earnings and sector momentum.

Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. It offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. The company was founded by Ming Hsieh on May 13, 2016 and is headquartered in El Monte, CA.

Fulgent Genetics Inc

Fulgent Genetics is trending as investors digest mixed sentiments around its financials and future prospects, with some seeing long-term value due to its cash reserves and diagnostics business. Discussions revolve around the impact of the pharma division, insider trading activity, and the potential for strategic moves like buybacks or acquisitions. Community members are closely watching price gaps and debating the stock's long-term direction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Y Intercept Hong Kong Ltd Acquires New Position in Disc Medicine, Inc. $IRON

Y Intercept Hong Kong Ltd bought a new position in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and...

What Makes Disc Medicine, Inc. (IRON) a Strong Momentum Stock: Buy Now?

Does Disc Medicine, Inc. (IRON) have what it takes to be a top stock pick for momentum investors? Let's find out.

Does Disc Medicine, Inc. (IRON) Have the Potential to Rally 26.29% as Wall Street Analysts Expect?

The consensus price target hints at a 26.3% upside potential for Disc Medicine, Inc. (IRON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Shares of Revolution Medicines, Disc Medicine, and Regeneron Pharmaceuticals rose in after-hours trading on Thursday after the U.S. Food and Drug Administration (FDA) announced the first group of drugs selected for expedited review under its new National Priority Voucher pilot program.In after-hours trading on Thursday,&nbsp;<a href="https://stocktwits.com/symbol/RVMD">Revolution Medicines</a> jumped 9%,&nbsp;<a href="https://stocktwits.com/symbol/IRON">Disc Medicine</a> surged 17%, and&nbsp;<a href="https://stocktwits.com/symbol/REGN">Regeneron Pharmaceuticals</a> edged up 0.1%.FDA Names 9 Drugs For Accelerated ReviewThe FDA said nine products have been chosen for the fast-track review process, which shortens decision timelines from the usual 10–12 months to just one or two months once a complete application is filed.The selected drugs include Merck KGaA’s fertility treatment Pergoveris, Sanofi’s Type 1 diabetes therapy teplizumab, Regeneron’s gene therapy DB-OTO for congenital deafness, and ketamine for domestic manufacturing of a general anesthetic.&nbsp;Also on the list are Revolution Medicines’ RMC-6236 for pancreatic cancer, Disc Medicine’s bitopertin for porphyria, Achieve Life Sciences’ cytisinicline for nicotine vaping addiction, Dompe’s cenegermin-bkbj for blindness, and Augmentin XR for domestic manufacturing of a common antibiotic.FDA Commissioner Highlights Expedited Review EffortFDA Commissioner Marty Makary said the initiative could shorten FDA decision times from a year to "a matter of weeks” by moving promising or high-impact therapies to the front of the review line.Makary said some of the drugs selected for vouchers, including one that uses ketamine as a general anesthetic, will be manufactured in the United States. He described Regeneron’s DB-OTO, a gene therapy for congenital deafness, as “an exciting treatment,” noting that “some of these kids got normal hearing from this amazing treatment.”He added that this is just the first round of vouchers, with additional selections expected in the coming weeks.How Stocktwits Traders Reacted To FDA’s Fast-Track ListOn Stocktwits, retail sentiment toward Revolution Medicines was ‘extremely bullish’ with ‘extremely high’ message volume, while Disc Medicine saw ‘neutral’ sentiment amid similarly ‘extremely high’ activity, and Regeneron registered ‘neutral’ sentiment with ‘normal’ engagement levels.One&nbsp; user said they expect Regeneron shares to climb steadily, projecting the stock could reach the $800-$900 range within two years.&nbsp;<stembedurl>https://stocktwits.com/Iwannagofast1/message/632653980</stembedurl>Another bullish trader suggested Revolution Medicines could be an attractive takeover candidate, potentially fetching twice its current value.<stembedurl>https://stocktwits.com/ChessGM/message/632555600</stembedurl>So far this year, Revolution Medicines shares have gained 14%, Disc Medicine is up 17%, while Regeneron has declined 20%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the FDA (United States Food and Drug Administration) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program

The FDA’s new National Priority Voucher pilot helps with faster drug reviews, cutting timelines from nearly a year to weeks.

Equity

Raymond James bullish on biotech firms on favorable valuation

Investing.com -- Raymond James started coverage on biotechnology companies, rating Avidity Biosciences and Disc Medicine at Strong Buy and assigning Outperform ratings to Dyne Therapeutics, Tectonic Therapeutic, and Wave Life Sciences (NASDAQ:WVE), pointing to a sector-wide opportunity amid “suppressed valuations.”

Disc Medicine (NASDAQ:IRON) Given "Outperform" Rating at Wedbush

Wedbush reaffirmed their outperform rating on shares of Disc Medicine (NASDAQ:IRON - Free Report) in a report issued on Monday morning, RTT News reports. Wedbush currently has a $43.00 price...

FY2024 Earnings Estimate for Disc Medicine, Inc. Issued By Wedbush (NASDAQ:IRON)

Disc Medicine, Inc. (NASDAQ:IRON - Free Report) - Wedbush boosted their FY2024 earnings per share (EPS) estimates for Disc Medicine in a report released on Monday, April 1st. Wedbush analyst D...

Leerink Partnrs Comments on Disc Medicine, Inc.'s Q2 2024 Earnings (NASDAQ:IRON)

Disc Medicine, Inc. (NASDAQ:IRON - Free Report) - Stock analysts at Leerink Partnrs reduced their Q2 2024 earnings per share estimates for shares of Disc Medicine in a report issued on Monday, April...

Raymond James Reiterates "Outperform" Rating for Disc Medicine (NASDAQ:IRON)

Disc Medicine (NASDAQ:IRON - Get Free Report)s stock had its "outperform" rating reaffirmed by analysts at Raymond James in a report issued on Monday, Marketbeat Ratings reports. They...

Analysts Offer Insights on Healthcare Companies: Assembly Biosciences (ASMB), Natera (NTRA) and Disc Medicine (IRON)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Assembly Biosciences (ASMB Research Report), Nater...

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$1.63	--	--	N/A
Q3 '25	-$1.44	-$1.77	-22.74%	MISSED
Q2 '25	-$1.13	-$1.58	-40.05%	MISSED
Q1 '25	-$1.11	-$1.02	7.87%	BEAT
Q4 '24	-$1.11	-$0.95	14.30%	BEAT

IRON
Disc Medicine Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest IRON News

IRONDisc Medicine Inc